For the first time, the
U.S.
food and Drug Administration (
FDA) has approved a
blood-thinning agent for the prevention of life-threatening
blood clots, also known as deep-vein
thrombosis (DVT), in
medical patients who are at risk for thromboembolic
complications due to severely restricted mobility during acute
illnesses.
Aventis Pharmaceuticals, the U.S. business of
Aventis Pharma AG, announced today that the
FDA has
approved the low-molecular-weight heparin, Clexane/
Lovenox
(enoxaparin
sodium) for the prevention of deep-vein
thrombosis, a condition that may
lead to
pulmonary embolism,
in patients with illnesses such as moderate or severe
heart
failure, respiratory failure, severe infection,
back pain,
vertebral
compression or arthritic episodes.
"This important addition to the approved uses of
Clexane/Lovenox will ensure the product's future growth by
making it available to benefit a significantly larger patient
population," said Richard Markham, Chief Executive Officer of
Aventis Pharma. "We are confident that Clexane/Lovenox will
continue to be the foundation therapy in the prevention and
treatment of venous and arterial thrombosis, and maintain its
global leadership of the low-molecular-weight heparin
market."
LANDMARK TRIAL ESTABLISHES NEED FOR BLOOD CLOT
PREVENTION
According to the MEDENOX (MEDical patients with
ENOXaparin) study published in The New England Journal of
medicine (Samama, 1999), hospitalized acutely
ILL medical
(non-surgical) patients are at significant risk for venous
thromboembolic
events (deep-vein thrombosis or pulmonary
embolism), and
prophylaxis with Lovenox significantly
reduces the risk across a range of patient categories.1
The MEDENOX study is a phase III multicenter,
three-parallel-group (enoxaparin 20 mg and 40 mg once daily
and
placebo), randomized, double-blind, placebo-controlled
study involving 1,102 patients from 60 centers in nine
countries. It is the first study of more than 1,000 patients
using venography to demonstrate that acutely ill medical
patients are at significant risk for
venous thromboembolism
(VTE). The study included patients that were initially
bedridden and suffering from heart failure, acute respiratory
failure, acute infectious disease, acute rheumatic
disorder, or
active episodes of irritable-bowel disease, combined with
pre-defined VTE
risk factors such as
obesity and varicose
veins.
The study demonstrated that enoxaparin
sodium 40 mg once
daily is effective in reducing the risk of VTE. Assessment of
efficacy results established that, at day 14, the incidence of
VTE was significantly lower in the enoxaparin 40 mg treated
group when compared with placebo (4.4% vs